Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.

Aspira Women’s Health Stock Up 3.1 %

AWH opened at $0.77 on Wednesday. The firm has a market cap of $12.87 million, a PE ratio of -0.64 and a beta of 1.39. The business has a fifty day simple moving average of $0.82 and a 200-day simple moving average of $1.04. Aspira Women’s Health has a fifty-two week low of $0.67 and a fifty-two week high of $5.65.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health at the end of the most recent quarter. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.